此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

心力衰竭患者的家庭心脏康复 (MOBILE HEART)

2026年9月29日 更新者:Brian Lindman、Vanderbilt University Medical Center

使用移动健康工具对心力衰竭患者进行家庭心脏康复(移动心脏):一项随机对照试验

The vast majority of individuals with heart failure do not participate in center based cardiac rehabilitation (CBCR). While steps to increase utilization of CBCR are important, many individuals will still not participate for a variety of reasons. This pilot randomized controlled trial is evaluating a home-based cardiac rehabilitation (HBCR) intervention delivered using a custom app and digital tools in patients with heart failure. After a brief roll-in period, participants are randomized to one of two groups: (1) control or (2) HBCR mobile health intervention. The intervention targets key health behaviors and includes traditional cardiac rehabilitation components. The study will assess the effect of the intervention on physical activity, quality of life, clinical events, and other outcomes.

研究概览

研究类型

介入性

注册 (估计的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Tennessee
      • Nashville、Tennessee、美国、37232
        • Vanderbilt University Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria Roll-in Phase

  1. Stage C HF (NYHA Class I-III) AND

    1. Discharged from a HF hospitalization OR
    2. Scheduled for appointment in a cardiology clinic with a prior HF hospitalization within the past 12 months OR
    3. Scheduled for appointment in a cardiology clinic with a KCCQ-SS <75
  2. Receives longitudinal HF care at VUMC, including at least one visit prior to the roll-in phase

Randomized Controlled Trial (beyond roll-in phase)

1. Willingness to continue and participate in the study visits and other study activities required for the RCT

Exclusion Criteria Roll-in Phase

  1. Unwilling or unable to provide informed consent for participation in the RCT
  2. Requires a wheelchair all (or most) of the time inside and outside the house; it is acceptable if a wheelchair is needed, for example, for parking lot transfer for a clinic visit and navigating around the hospital without it being needed in the home
  3. If an individual uses a walker or cane all (or most) of the time, then he/she will be excluded if he/she scores 2 or lower on the Mini-Cog or the patient is unable to perform 2 chair sit-to-stands independently or is deemed to be at high fall risk during baseline visit assessment.
  4. History of falls over the last 6 months; an isolated explainable fall with no injury would not exclude the patient, but a tendency to falls indicative of balance/stability issues would exclude the patient.
  5. Age < 18 years
  6. Stage D HF (advanced HF under evaluation for LVAD or transplant)
  7. NYHA class IV symptoms
  8. Congenital heart disease
  9. Pregnant
  10. Group 1 pulmonary hypertension
  11. Moderate-severe or severe (> 3+) mitral or aortic valvular disease
  12. Physical or neuropsychiatric limitations that would prevent proficient use of the study tools and successful completion of the physical and quality of life assessments (e.g. blindness, dementia)
  13. Planned surgery within 3 months
  14. Planned discharge from hospital to hospice, assisted living, or inpatient rehabilitation facility (discharge to a senior facility permitted as long as they are considered Independent Living)
  15. Treating provider or study team physician indicates that participation in the RCT would be unsafe
  16. Participation in any ongoing randomized trial that has not completed follow-up

Randomized Controlled Trial (beyond roll-in phase)

  1. Not adherent to wearing the Actigraph activity tracker during the roll-in phase for a minimum of 4 (out of 10) compliant days (worn ³10 hours/day). Allowance will be made to include participants who wear the ActiGraph device ³10 hours/day for 3 days and also wear the ActiGraph device >9 hours/day for at least 1 day.
  2. Unable to complete the baseline study visit within 4 weeks of the completion of the roll-in actigraphy assessment.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Home-based cardiac rehabilitation mobile health intervention

Home-based cardiac rehabilitation with mobile application and periodic video calls with exercise physiologist + AHA Life's Essential 8 sheets.

Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.

无干预:Control

Standard of care course for an individual not participating in center based cardiac rehabilitation. AHA Life's Essential 8 Fact Sheets are provided to promote healthy living.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Average daily total activity counts
大体时间:The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily total activity counts determined. The primary comparison will be at 12 weeks after randomization.

Daily total activity counts are determined by a triaxial actigraphy device.

The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily total activity counts determined. The primary comparison will be at 12 weeks after randomization.

次要结果测量

结果测量
措施说明
大体时间
血压
大体时间:比较将在随机化后 12 周进行。
比较将在随机化后 12 周进行。
Average daily active minutes
大体时间:The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily activity minutes determined. The comparison will be at 12 weeks after randomization.

Daily active minutes are determined by a triaxial actigraphy device.

The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily activity minutes determined. The comparison will be at 12 weeks after randomization.
Average daily steps
大体时间:The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily steps determined. The comparison will be at 12 weeks after randomization.

Daily steps are determined by a triaxial actigraphy device.

The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily steps determined. The comparison will be at 12 weeks after randomization.
Average daily energy expenditure
大体时间:The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily energy expenditure determined. The comparison will be at 12-weeks after randomization.

Average daily energy expenditure is determined by a triaxial actigraphy device.

The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily energy expenditure determined. The comparison will be at 12-weeks after randomization.
Average daily moderate to vigorous active minutes
大体时间:The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily moderate to vigorous active mins determined. The comparison will be at 12-weeks after randomization.

Daily moderate to vigorous active minutes are determined by a triaxial actigraphy device.

The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily moderate to vigorous active mins determined. The comparison will be at 12-weeks after randomization.
Sustained physical activity bursts of 10 minutes or greater per day
大体时间:The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily steps determined. The comparison will be at 12 weeks after randomization.

Physical activity bursts are determined by a triaxial actigraphy device.

The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily steps determined. The comparison will be at 12 weeks after randomization.
6 minute walk distance
大体时间:The comparison will be at 12-weeks after randomization.

The distance walked in 6 minutes.

The comparison will be at 12-weeks after randomization.
Chair sit to stand time
大体时间:The comparison will be at 12-weeks after randomization.

The time taken to complete 5 chair rises.

The comparison will be at 12-weeks after randomization.
5 meter gait speed
大体时间:The comparison will be at 12-weeks after randomization.

The speed of walking 5 meters (meters/second).

The comparison will be at 12-weeks after randomization.
Balance test
大体时间:The comparison will be at 12-weeks after randomization.

Score based on ability to stand unsupported for 10 seconds with feet in a certain position (feet together, semi tandem, full tandem). Score ranges from 0-4 (higher score is better).

The comparison will be at 12-weeks after randomization.
AM-PAC Basic Mobility Outpatient Short Form (Low Function)
大体时间:The comparison will be at 12-weeks after randomization.

Basic mobility will be assessed with the Activity Measure for Post-Acute Care (AM-PAC) Basic Mobility Outpatient Short Form (Low Function); (raw score range 0-39, higher score is better)

The comparison will be at 12-weeks after randomization.
Short Physical Performance Battery Score
大体时间:The comparison will be at 12-weeks after randomization.

Composite score including 3 components (Chair sit to stand, 5 meter gait speed, balance test). Score ranges from 0-12 (higher score is better).

The comparison will be at 12-weeks after randomization.
Heart-failure specific health status assessed by the KCCQ
大体时间:The comparison will be at 12-weeks after randomization.

Assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ); (score range 0-100, higher is better health status).

The comparison will be at 12-weeks after randomization.
Physical health status assessed by the PROMIS 10
大体时间:The comparison will be at 12-weeks after randomization.

Global physical health score from the PROMIS 10 Global Health Short Form questionnaire (raw score range 4-20, higher is better).

The comparison will be at 12-weeks after randomization.
Mental health status assessed by the PROMIS 10
大体时间:The comparison will be at 12-weeks after randomization.

Global mental health score from the PROMIS 10 Global Health Short Form questionnaire (raw score range 4-20, higher is better)

The comparison will be at 12-weeks after randomization.
Mood disturbance assessed by PHQ9
大体时间:The comparison will be at 12-weeks after randomization.

Patient health questionnaire 9 (PHQ9); (score range 1-27, lower is better)

The comparison will be at 12-weeks after randomization.
Behavioral Regulation In Exercise Questionnaire 3
大体时间:The comparison will be at 12-weeks after randomization.

Behavioral Regulation In Exercise Questionnaire 3 (BREQ-3); (score range per question of 0-4, higher is better).

The comparison will be at 12-weeks after randomization.
Social support and exercise survey
大体时间:The comparison will be at 12-weeks after randomization.

Social support and exercise survey (score range per question of 1-5, higher is better).

The comparison will be at 12-weeks after randomization.
Multidimensional Self-Efficacy for Exercise Scale
大体时间:The comparison will be at 12-weeks after randomization.

Multidimensional Self-Efficacy for Exercise Scale (MSES); (score range per question of 0-10, higher is better).

The comparison will be at 12-weeks after randomization.
General self-efficacy scale
大体时间:The comparison will be at 12-weeks after randomization.

General self-efficacy scale (GSE); (score range per question of 1-4, higher is better).

The comparison will be at 12-weeks after randomization.
Modified Heart Failure Collaborative GDMT score
大体时间:The comparison will be at 12-weeks after randomization in patients with LVEF of 40% or less.

Guideline directed medical therapy (GDMT) score includes 4 components of RAASi, BB, SGLT2i, and MRA (maximum score of 9, higher scores indicate increased GDMT utilization).

The comparison will be at 12-weeks after randomization in patients with LVEF of 40% or less.
Probability of the hierarchical clinical event composite
大体时间:Over the entire available follow-up period for randomized participants (minimum of 12 weeks).

The hierarchical clinical event composite includes (in order of hierarchy): (1) all-cause death and (2) all-cause hospitalization. To examine whether the intervention improves mortality and hospitalization, in heart failure patients, we will conduct Bayesian Markov longitudinal proportional odds model on weekly outcome measures. The active treatment vs. control group comparison (primary comparison for the trial) will be estimated by contrasting the average of posterior probability that Y≥y of the active treatment group to the control group.

Over the entire available follow-up period for randomized participants (minimum of 12 weeks).
All-cause unplanned rehospitalization
大体时间:Over the entire available follow-up period for randomized participants (minimum of 12 weeks).

This includes inpatient, observation, or ER visit.

Over the entire available follow-up period for randomized participants (minimum of 12 weeks).
Worsening heart failure event
大体时间:Over the entire available follow-up period for randomized participants (minimum of 12 weeks).

This includes inpatient, observation, ER visit, or urgent clinic visit for worsening heart failure.

Over the entire available follow-up period for randomized participants (minimum of 12 weeks).
All-cause mortality
大体时间:Over the entire available follow-up period for randomized participants (minimum of 12 weeks).

Death for any reason.

Over the entire available follow-up period for randomized participants (minimum of 12 weeks).
"Thriving patient" composite
大体时间:The comparison will be made at 12 weeks.

Percent of patients that meet the following criteria: 1) alive 2) no all-cause hospitalization 3) Improvement in average daily total activity counts by 10% or greater from baseline to 12 weeks.

The comparison will be made at 12 weeks.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Brian R Lindman, MD, MSCI、Vanderbilt University Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年8月5日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2027年8月1日

研究注册日期

首次提交

2024年6月24日

首先提交符合 QC 标准的

2024年6月24日

首次发布 (实际的)

2024年6月28日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 240749

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅